JAZZ Stock Cash Flow Statements

Jazz Pharmaceuticals plc Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Jazz Pharmaceuticals plc Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30

operating activities
net income	-718,470,000	-92,541,000		215,055,000	168,568,000	-14,618,000		146,820,000	104,438,000	69,420,000		-19,648,000	34,665,000	1,647,000		-52,833,000	-363,316,000	121,832,000		148,234,000	114,801,000	-157,833,000	102,276,000	261,898,000	85,201,000	149,316,000	92,321,000	45,991,000	63,526,000	105,604,000	86,511,000	87,145,000	111,282,000	74,121,000	87,960,000	88,113,000	70,700,000	25,768,000	43,586,000	-93,639,000	75,409,000	42,185,000	43,425,000	33,209,000	27,145,000	27,681,000	37,473,000	32,482,000	33,202,000	21,827,000	24,459,000	13,243,000	-6,388,000	1,464,000	5,653,000	-1,672,000	2,171,000	-12,988,000	-56,940,000	-28,810,000	-51,879,000	-46,710,000	-60,020,000	-19,359,000
adjustments to reconcile net income to net cash from operating activities:
acquired in-process research and development				0	0	10,000,000		0	0	1,000,000		0								10,000,000	3,000,000	202,250,000	51,775,000	2,200,000	56,000,000				75,000,000			15,000,000	0	8,750,000				75,000,000	0	127,000,000
intangible asset amortization	162,103,000	154,448,000		157,457,000	155,223,000	155,730,000		154,883,000	152,062,000	149,786,000		141,232,000	148,456,000	172,094,000		159,804,000	140,480,000	68,192,000		66,684,000	62,974,000	62,847,000	62,863,000	61,576,000	56,885,000	46,989,000	54,959,000	53,007,000	47,313,000	26,186,000	25,665,000	26,453,000	26,737,000	22,642,000	26,127,000	23,668,000	24,677,000
share-based compensation	64,501,000	67,653,000		59,760,000	56,654,000	61,441,000		56,115,000	61,433,000	56,352,000		56,681,000	53,687,000	50,070,000		53,239,000	48,163,000	34,485,000		30,356,000	30,604,000	28,654,000	28,785,000	28,289,000	27,552,000	25,103,000	26,312,000	24,303,000	27,126,000	27,260,000	25,193,000	24,874,000	25,433,000	24,183,000	23,114,000	23,300,000	20,819,000	18,251,000	18,552,000	13,815,000	11,876,000	11,506,000	8,757,000
acquisition accounting inventory fair value step-up adjustment	37,109,000	29,880,000		35,034,000	33,243,000	28,943,000		30,822,000	27,814,000	60,458,000		70,964,000	68,282,000	63,943,000		82,646,000
depreciation	11,906,000	10,425,000		7,775,000	7,812,000	7,653,000		7,675,000	7,515,000	7,574,000		7,594,000	7,747,000	7,617,000		7,773,000	6,835,000	4,779,000		4,810,000	4,739,000	4,527,000	3,991,000	3,355,000	3,539,000	3,906,000	3,735,000	3,722,000	3,065,000	3,093,000	3,130,000	3,121,000	2,517,000	2,527,000	2,548,000	2,363,000	2,232,000	1,868,000	1,860,000	1,309,000	895,000	595,000	575,000	374,000	229,000	186,000	111,000	79,000	85,000	104,000	173,000	188,000	224,000	301,000	326,000	364,000	369,000	370,000	438,000	609,000	627,000	524,000
non-cash interest expense	4,848,000	17,066,000		7,677,000	5,212,000	5,988,000		6,062,000	5,427,000	4,766,000		14,262,000	5,572,000	12,168,000		28,045,000																																										535,000	625,000	592,000	513,000	330,000
benefit from losses on accounts receivable and inventory	1,452,000	5,319,000		2,680,000	5,783,000	7,403,000		2,182,000	3,234,000	2,316,000		6,916,000	3,980,000	2,170,000		4,702,000	7,659,000	1,083,000		5,070,000	1,458,000	2,620,000	1,444,000	1,875,000	528,000	2,064,000	2,080,000	590,000	277,000	600,000	948,000	76,000	790,000	898,000	3,411,000	184,000	426,000	948,000	1,112,000	813,000	522,000	1,094,000	142,000
deferred tax benefit	-66,419,000	-43,833,000		-64,404,000	-75,183,000	-66,385,000		-78,922,000	-79,334,000	-66,061,000				-45,339,000				-19,110,000		-38,141,000	-18,792,000	-63,976,000	-16,588,000	-134,294,000	-17,053,000
other non-cash transactions	13,579,000	-6,537,000		4,095,000	846,000	14,674,000		6,106,000	31,383,000	16,773,000		2,743,000	-14,394,000	-14,701,000		6,639,000	-4,783,000	7,766,000		9,176,000	1,594,000	1,902,000	-1,890,000	-3,728,000	1,181,000	-4,026,000	-5,030,000	16,026,000	6,480,000	6,595,000	1,405,000	493,000	-612,000	1,579,000	-11,772,000	7,306,000	632,000	-2,686,000	1,039,000	1,868,000	1,184,000	1,276,000	1,975,000	1,462,000	-2,102,000	2,411,000
changes in assets and liabilities:
accounts receivable	-55,519,000	66,049,000		-22,256,000	8,720,000	-8,443,000		-18,858,000	13,979,000	28,460,000		-9,637,000	-24,508,000	-9,723,000		6,882,000	-16,593,000	-18,245,000		-8,644,000	-34,221,000	37,861,000	43,267,000	9,386,000	-56,960,000	-1,162,000	2,235,000	-56,591,000	-19,235,000	5,445,000	-8,483,000	-6,116,000	-8,356,000	-13,802,000	-2,182,000	-3,710,000	-4,769,000	-28,801,000	-5,875,000	-16,014,000	1,366,000	-20,104,000	-18,911,000	-10,346,000	1,367,000	-8,794,000	-2,946,000	-6,429,000	-3,616,000	698,000	-7,967,000	-19,000	-2,140,000	358,000	-3,111,000	-5,000	-2,185,000	-369,000	43,000	-1,465,000	89,000	79,000	927,000	-104,000
inventories	-26,231,000	-35,621,000		-9,286,000	-4,747,000	-12,844,000		-4,934,000	-816,000	-6,266,000		-8,529,000	-17,117,000	-24,812,000		-4,489,000	-7,388,000	-22,014,000		-3,035,000	-8,591,000	-10,235,000	-4,466,000	-9,874,000	-8,688,000	1,355,000	-5,626,000	-3,312,000	-1,253,000	-1,621,000	-4,258,000	933,000	-8,743,000	-6,307,000	-1,746,000	-7,000	-1,842,000	-6,882,000	-231,000	-3,071,000	2,659,000	-7,335,000	1,231,000	909,000	864,000	-58,000	506,000	440,000	302,000	50,000	-613,000	-49,000	-911,000	-71,000	631,000	-329,000	223,000	358,000	1,450,000	-56,000	-4,038,000	10,000	1,026,000	-2,000
prepaid expenses and other current assets	-28,065,000	36,277,000		-34,164,000	-20,075,000	54,947,000		-33,935,000	-45,424,000	42,032,000		1,147,000	-516,000	23,170,000		-13,371,000	-18,454,000	-2,897,000		-20,049,000	-27,010,000	-17,843,000	-6,929,000	-14,941,000	-988,000	12,257,000	-1,734,000	-3,534,000	-9,720,000	9,767,000	-10,637,000	1,823,000	-9,104,000	-1,231,000	8,378,000	1,994,000	-15,670,000	3,326,000	-3,421,000	4,357,000	3,372,000	-8,400,000	-6,272,000	1,547,000	-3,173,000	-2,217,000	117,000	769,000	-978,000	-842,000	817,000	121,000	173,000	-685,000	1,571,000	258,000	522,000	259,000	949,000	193,000	500,000	-951,000	361,000	-764,000
operating lease assets	6,527,000	5,913,000		3,498,000	3,496,000	3,703,000		2,845,000	7,070,000	4,508,000		3,733,000	3,844,000	3,095,000		4,161,000	4,203,000	3,690,000		3,308,000	3,227,000	3,195,000	3,520,000
other non-current assets	-50,000	-752,000		-3,845,000	-1,609,000	-4,090,000		-7,973,000	-3,367,000	-9,541,000		-3,677,000	-1,308,000	979,000		-1,664,000	-330,000	157,000		11,959,000	1,659,000	323,000	1,557,000	268,000	426,000
accounts payable	-12,666,000	19,131,000		-12,790,000	15,449,000	-19,597,000		10,243,000	-26,824,000	34,286,000		28,959,000	2,846,000	-27,617,000		-142,000	-31,983,000	51,292,000		15,381,000	-14,340,000	19,604,000	43,200,000	-15,650,000	1,554,000	2,745,000	-15,765,000	23,136,000	783,000	-518,000	5,865,000	-10,512,000	-4,440,000	10,664,000	2,697,000	-1,174,000	3,303,000	-2,310,000	-40,134,000	8,579,000	1,963,000	-11,451,000	16,158,000	-13,906,000	6,714,000	4,649,000	-3,334,000	3,798,000	1,017,000	599,000	-842,000	-2,512,000	2,518,000	1,727,000	-3,082,000	1,166,000	-480,000	-1,182,000	-878,000	-1,908,000	-393,000	6,059,000	-16,000	-1,036,000
accrued liabilities	-256,389,000	181,038,000		51,024,000	-29,273,000	34,677,000		13,547,000	7,177,000	-96,985,000		62,294,000	-21,189,000	-23,241,000		36,846,000	42,969,000	13,719,000		33,482,000	5,226,000	-12,198,000	21,662,000	-56,346,000	-2,685,000	4,966,000	12,624,000	47,484,000	9,489,000	-17,329,000	-15,743,000	-4,058,000	1,117,000	-6,706,000	22,777,000	-650,000	-17,485,000	20,289,000	-1,748,000	927,000	9,311,000	-5,089,000	-2,660,000	-4,012,000	22,878,000	-6,539,000	-1,051,000	9,121,000	3,439,000	-298,000	4,497,000	3,171,000	536,000	1,072,000	2,707,000	-5,409,000	597,000	-90,000	-655,000	-7,947,000	2,753,000	476,000	5,501,000	1,820,000
income taxes payable	46,282,000	12,988,000		2,068,000	3,172,000	14,858,000		15,222,000	20,524,000	25,413,000		4,296,000	-21,235,000	16,767,000		31,010,000	-46,464,000	24,625,000		-30,392,000	24,652,000	20,829,000	13,763,000	-10,676,000	39,726,000	-10,714,000	-17,468,000	14,183,000	6,008,000	-28,266,000	30,753,000	-75,000	-22,360,000	25,758,000	2,496,000	-23,666,000	30,163,000	13,549,000	-303,000	5,757,000	2,812,000	-20,501,000	-1,397,000
operating lease liabilities, less current portion	-1,797,000	-1,090,000		-2,792,000	-3,929,000	-2,980,000		-1,905,000	-6,991,000	-4,959,000		-4,054,000	-4,170,000	-3,915,000		-4,633,000	-4,608,000	-4,182,000		-2,906,000	-3,072,000	-3,906,000	-3,568,000
other non-current liabilities	792,000	3,971,000		2,161,000	1,990,000	-3,831,000		1,200,000	17,465,000	1,835,000		-4,295,000	5,932,000	5,130,000		5,136,000	6,569,000	4,774,000		7,342,000	18,596,000	7,316,000	-17,811,000	7,404,000	6,773,000	-6,711,000	6,304,000	7,651,000	-2,602,000	7,359,000	8,174,000	3,765,000	7,195,000	7,392,000	5,198,000	6,451,000	6,820,000	4,449,000	3,772,000	4,689,000	3,416,000	3,513,000	3,196,000
net cash from operating activities	88,855,000	429,784,000	398,580,000	398,747,000	331,352,000	267,229,000	167,339,000	307,195,000	296,765,000	320,708,000	341,971,000	417,991,000	303,036,000	208,979,000	177,755,000	274,060,000	41,695,000	284,997,000	186,271,000	257,889,000	182,519,000	272,969,000	337,503,000	148,847,000	202,253,000	220,575,000	191,624,000	162,359,000	188,897,000	135,091,000	164,540,000	136,531,000	129,594,000	143,716,000	175,076,000	140,571,000	96,555,000	129,697,000	74,924,000	68,723,000	129,800,000	8,719,000	65,890,000	44,143,000	76,969,000	24,295,000	43,659,000	46,053,000	37,436,000	24,448,000	31,275,000	18,486,000	2,607,000	6,500,000	1,772,000	-11,442,000	-1,058,000	-5,150,000	-18,786,000	-28,689,000	-44,587,000	-38,170,000	-28,061,000	-15,371,000
capex	-12,967,000	-13,881,000	0	-10,788,000	-7,091,000	-6,904,000	0	-4,299,000	-5,739,000	-3,822,000	0	4,902,000	-12,278,000	-12,292,000	0	-8,328,000	-7,178,000	-2,168,000	0	-3,369,000	-2,690,000	-4,830,000	-11,087,000	-13,963,000	-7,948,000	-3,940,000	-4,132,000	-7,149,000	-8,347,000	-8,151,000	-3,574,000	-2,382,000	-1,701,000	-2,472,000	-5,159,000	-13,022,000	-14,410,000	-8,139,000	-11,133,000	-3,527,000	-2,164,000	-3,567,000	-1,143,000	-2,499,000	-2,209,000	-285,000	-756,000	-362,000	-95,000	-66,000	-113,000	-316,000	-216,000	-86,000	-6,000	-30,000	-12,000	-5,000	-74,000	-56,000	-1,151,000	-458,000	-1,043,000	-593,000
free cash flows	75,888,000	415,903,000	398,580,000	387,959,000	324,261,000	260,325,000	167,339,000	302,896,000	291,026,000	316,886,000	341,971,000	422,893,000	290,758,000	196,687,000	177,755,000	265,732,000	34,517,000	282,829,000	186,271,000	254,520,000	179,829,000	268,139,000	326,416,000	134,884,000	194,305,000	216,635,000	187,492,000	155,210,000	180,550,000	126,940,000	160,966,000	134,149,000	127,893,000	141,244,000	169,917,000	127,549,000	82,145,000	121,558,000	63,791,000	65,196,000	127,636,000	5,152,000	64,747,000	41,644,000	74,760,000	24,010,000	42,903,000	45,691,000	37,341,000	24,382,000	31,162,000	18,170,000	2,391,000	6,414,000	1,766,000	-11,472,000	-1,070,000	-5,155,000	-18,860,000	-28,745,000	-45,738,000	-38,628,000	-29,104,000	-15,964,000
investing activities
asset acquisition, net of cash acquired
acquisition of investments	-240,000,000	-440,050,000		-130,125,000	-330,000,000	-375,000,000		-190,000,000				-300,000				-594,000	-5,400,000	-20,700,000		-621,275,000	-855,475,000	-185,000,000	-225,000,000	-245,975,000	-115,000,000	-415,000,000	-265,000,000	-235,000,000	-270,000,000			-11,209,000	-52,711,000	-773,000
purchases of property, plant and equipment	-12,967,000	-13,881,000		-10,788,000	-7,091,000	-6,904,000		-4,299,000	-5,739,000	-3,822,000		4,902,000	-12,278,000	-12,292,000		-8,328,000	-7,178,000	-2,168,000		-3,369,000	-2,690,000	-4,830,000	-11,087,000	-13,963,000	-7,948,000	-3,940,000	-4,132,000	-7,149,000
acquisition of intangible assets	0	-25,000,000										0	0	-25,000,000						0	-100,000,000	-13,000,000	-55,000,000			2,000						0									0
proceeds from maturity of investments	470,000,000	310,000,000		355,000,000	80,000,000	120,000,000										0	335,000,000	760,000,000		355,000,000	220,000,000	345,000,000	190,000,000	285,000,000	345,000,000	180,000,000	190,000,000	195,000,000
net cash from investing activities	-641,020,000	-168,931,000	-193,287,000	214,087,000	-257,091,000	-271,904,000	101,798,000	-174,299,000	-85,739,000	-4,822,000	-324,378,000	4,602,000	-89,162,000	-37,292,000	-10,092,000	-26,813,000	-5,912,370,000	737,132,000	73,219,000	-279,644,000	-741,165,000	-60,080,000	-159,661,000	-2,638,000	166,052,000	-190,846,000	-190,234,000	-47,149,000	-203,347,000	-30,151,000	-3,574,000	-1,531,034,000	-204,412,000	-11,995,000	-5,159,000	-12,022,000	18,293,000	-83,139,000	-13,133,000	-957,203,000	-2,164,000	-3,567,000	-2,443,000	-3,749,000	-561,242,000	82,508,000	-65,599,000	-13,622,000	-820,000	-1,191,000	-1,113,000	-806,000	-1,175,000	951,000	-5,044,000	-1,905,000	-312,000	1,137,000	-6,994,000	6,220,000	-8,241,000	-2,927,000	9,405,000	-11,470,000
financing activities
repayments of long-term debt	-7,750,000	-757,750,000		-7,750,000	-7,750,000	-7,750,000		-7,750,000	-7,750,000	-7,750,000		-307,746,000	-7,754,000	-258,764,000		-258,760,000	-575,921,000	-8,347,000		-8,347,000	-8,346,000	-8,347,000	-8,347,000	-8,346,000	-8,347,000	-8,347,000	0	-9,023,000	-9,023,000	-9,024,000	-9,023,000	0	-9,885,000	-9,397,000	-961,000	-893,118,000	-2,284,000
share repurchases				-150,001,000				-74,371,000				0								0	-7,484,000	-139,053,000	-19,997,000	-59,869,000	-111,249,000	-21,454,000	-21,015,000	-34,546,000	-25,566,000	-16,963,000	-13,896,000	-96,575,000	-28,879,000	-134,365,000	-9,612,000	-1,352,000	-10,338,000	-6,486,000			-48,819,000
payment of employee withholding taxes related to share-based awards	-2,249,000	-67,163,000		-1,605,000	-2,847,000	-49,296,000		-1,884,000	-4,188,000	-43,266,000		-2,567,000	-6,289,000	-33,776,000		-2,431,000	-3,388,000	-23,784,000		-1,097,000	-1,116,000	-13,547,000	-1,087,000	-1,003,000	-13,810,000	-1,169,000	-1,429,000	-14,594,000	-1,589,000	-1,889,000	-14,431,000	-6,317,000	-1,802,000	-12,476,000	-8,723,000	-1,901,000	-14,778,000	-6,755,000	-1,188,000	-9,363,000	-3,706,000	-170,000	-1,427,000
proceeds from employee equity incentive and purchase plans	10,497,000	11,447,000		17,000	10,940,000	494,000		5,512,000	10,866,000	21,228,000		21,260,000	24,874,000	21,729,000		14,822,000	51,882,000	50,407,000		10,088,000	10,987,000	13,264,000	9,968,000	13,065,000	3,057,000	16,998,000	56,470,000	10,588,000	3,722,000			3,340,000
net cash from financing activities	-124,525,000	-813,466,000	-8,275,000	246,428,000	-161,085,000	-56,552,000	-100,306,000	-78,493,000	-96,667,000	-29,788,000	19,596,000	-289,053,000	10,777,000	-270,811,000	-246,609,000	-465,181,000	4,664,036,000	18,276,000	55,878,000	-22,656,000	642,534,000	-147,683,000	-19,463,000	-56,153,000	-130,349,000	-13,972,000	28,873,000	-47,575,000	27,028,000	-214,481,000	-181,674,000	891,722,000	-34,170,000	-144,520,000	-94,424,000	7,223,000	-3,261,000	263,267,000	-39,455,000	497,662,000	-45,722,000	47,456,000	3,133,000	-5,488,000	468,653,000	-18,225,000	2,801,000	-33,612,000	719,000	-2,990,000	-8,221,000	-4,401,000	-10,856,000	-4,048,000	6,637,000	9,805,000	127,000	-3,875,000	776,000	21,174,000	3,259,000	38,923,000	1,629,000	-1,187,000
effect of exchange rates on cash and cash equivalents	4,624,000	1,695,000	-2,289,000	3,071,000	-759,000	-1,698,000	1,789,000	-1,017,000	34,000	331,000	4,935,000	-5,447,000	-4,221,000	-1,489,000	-1,386,000	-1,686,000	506,000	-641,000	459,000	271,000	592,000	-948,000	-943,000	217,000	-112,000	-1,820,000	1,649,000	-501,000	824,000	1,759,000	1,740,000	1,382,000	-2,826,000	3,794,000	1,723,000	3,268,000	-13,026,000	-3,040,000	45,000	188,000	2,241,000	1,188,000	-3,265,000	344,000
net decrease in cash and cash equivalents	-672,066,000	-550,918,000																											13,402,000	-107,782,000	-18,968,000																									-3,542,000	-1,243,000	-7,888,000				-2,174,000
cash and cash equivalents, at beginning of period	0	2,412,864,000		0	0	1,506,310,000		0	0	881,482,000		0	0	591,448,000		0	0	1,057,769,000		0	0	637,344,000	0	0	309,622,000	0	0	386,035,000	0	0	365,963,000	0	0	988,785,000	0	0	684,042,000	0	0	636,504,000	0	0	387,196,000	0	0	82,076,000	0	0	0	44,794,000	0	0	0	15,595,000	0	0	0	24,903,000	0	0	0	102,945,000	0	0
cash and cash equivalents, at end of period	-672,066,000	1,861,946,000		862,333,000	-87,583,000	1,443,385,000		53,386,000	114,393,000	1,167,911,000		128,093,000	220,430,000	490,835,000		-219,620,000	-1,206,133,000	2,097,533,000		-44,140,000	84,480,000	701,602,000	157,436,000	90,273,000	547,466,000	13,937,000	31,912,000	453,169,000	13,402,000	-107,782,000	346,995,000	-501,399,000	-111,814,000	979,780,000	77,216,000	139,040,000	782,603,000	306,785,000	22,381,000	245,874,000	84,155,000	53,796,000	450,511,000	35,250,000	-16,111,000	170,654,000	-19,139,000	-1,181,000	37,335,000	65,061,000	21,941,000	13,279,000	-9,424,000	18,998,000	3,365,000	-3,542,000	-1,243,000	17,015,000	-25,004,000	-1,295,000	-49,569,000	100,771,000	-17,027,000	-28,028,000
net increase in cash and cash equivalents			194,729,000	862,333,000	-87,583,000	-62,925,000	170,620,000	53,386,000	114,393,000	286,429,000	42,124,000	128,093,000	220,430,000	-100,613,000	-80,332,000	-219,620,000	-1,206,133,000	1,039,764,000	315,827,000	-44,140,000	84,480,000	64,258,000	157,436,000	90,273,000	237,844,000	13,937,000	31,912,000	67,134,000				-501,399,000	-111,814,000	-9,005,000	77,216,000	139,040,000	98,561,000	306,785,000	22,381,000	-390,630,000	84,155,000	53,796,000	63,315,000	35,250,000	-16,111,000	88,578,000	-19,139,000	-1,181,000	37,335,000	20,267,000	21,941,000			3,403,000					-25,004,000	-1,295,000			-17,027,000	-28,028,000
deferred revenue								0	0	-459,000		-523,000	-524,000	-523,000		-697,000	-274,000	-637,000		-1,180,000	-1,180,000	-1,180,000	-1,180,000	-1,180,000	-1,874,000	-1,874,000	-1,874,000	-1,875,000	-2,157,000	-2,170,000	27,490,000	-206,000	-210,000	-266,000	-277,000	-97,000	-285,000	-361,000	-284,000	-273,000	-284,000	-285,000	-207,000	-298,000	535,000	-285,000	-284,000	-513,000	-479,000	3,000	-2,424,000	-296,000	-69,000	249,000	-110,000	-134,000	-10,540,000	-2,000	-362,000	8,685,000	1,652,000	-285,000	-789,000	-313,000
net proceeds from issuance of exchangeable senior notes, due 2030
repayment of exchangeable senior notes, due 2024
impairment charge																				0	0	136,139,000
loss on disposal of a business												-1,556,000
proceeds from sale of a business												0
deferred tax expense												-64,559,000
acquisition of a business, net of cash acquired																0
net proceeds from issuance of borrowings under credit agreement																0
net proceeds from issuance of senior secured notes, due 2029																0
payments for repurchase of exchangeable senior notes, due 2021
deferred tax provision																-74,994,000
net proceeds from issuance of exchangeable senior notes, due 2026																				0
net proceeds from revolving credit facility
repayments under revolving credit facility																				0									-500,000,000	-200,000,000	-150,000,000
payments for partial repurchase of exchangeable senior notes, due 2021																				-23,300,000
amortization of debt discount and deferred financing costs																		15,688,000		15,820,000	12,793,000	12,000,000	11,831,000	11,451,000	11,133,000	11,165,000	10,887,000	10,617,000	7,855,000	5,764,000	5,615,000	5,642,000	5,414,000	5,362,000
loss on extinguishment of debt																				614,000																											150,000
acquisitions, net of cash acquired																																						0	0	-828,676,000				0
proceeds from revolving credit facility																				0
loss on disposal of assets																						73,000	1,000	4,000	3,000
impairment charges																										0
loss on extinguishment and modification of debt																										0									0						0
net proceeds from sale of assets
proceeds from tenant improvement allowance on build-to-suit lease																										0
payment of debt modification costs																										0
deferred income taxes																										-12,430,000	-16,921,000	-15,307,000	-23,403,000	-14,956,000	-15,000,000	-15,410,000	910,000	-1,962,000	-8,495,000	-7,612,000	-9,261,000	-17,648,000	-14,220,000	-4,378,000	-8,898,000	-5,190,000	-3,874,000
other long-term assets																										-2,911,000	405,000	-3,988,000	442,000	-97,000	-2,170,000	-524,000	-2,411,000	-1,985,000	-2,897,000	-3,380,000	-3,278,000	-2,410,000	-1,820,000	-1,545,000	-804,000	-1,618,000	-999,000
net proceeds from issuance of debt																																			-2,043,000			559,011,000	0	636,355,000	0			0
loss on disposal of property, plant and equipment																											-141,000	256,000
loss on disposal of property and equipment																													-97,000	375,000	82,000	-34,000	0	37,000	71,000	38,000	8,000			2,000	7,000	0	40,000	7,000			18,000	0			-34,000				0	0	5,000	9,000	830,000	0			0	0
purchases of property and equipment																													-8,347,000	-8,151,000	-3,574,000	-2,382,000	-1,701,000	-2,472,000	-5,159,000	-13,022,000	-14,410,000	-8,139,000	-11,133,000	-3,527,000	-2,164,000	-3,567,000	-1,143,000	-2,499,000	-2,209,000	-285,000	-756,000	-362,000	-95,000	-66,000	-113,000	-316,000	-216,000	-86,000	-6,000	-30,000	-12,000	-5,000	-74,000	-56,000	-1,151,000	-458,000	-1,043,000	-593,000
acquisition of in-process research and development																																-15,000,000	0	-8,750,000				-75,000,000	-2,000,000	-125,000,000
proceeds from employee equity incentive and purchase plans and exercise of warrants																															5,676,000				7,295,000			16,810,000	10,175,000	21,467,000	8,114,000
excess tax benefit from share-based compensation																																	4,435,000	-7,938,000			-10,635,000	-3,283,000	4,985,000	-5,777,000			-889,000	1,972,000	-4,324,000	-1,914,000
net proceeds from sale of business																																			0	1,000,000	32,703,000
acquisition of noncontrolling interests																																						-310,000	-17,465,000	-119,175,000
proceeds from employee equity incentive plans																																		3,780,000
acquisition accounting inventory fair value step-up adjustments																																						0	2,455,000	8,022,000
contingent consideration																																						0	0	-14,900,000
payment of contingent consideration																																						0	0	-35,100,000
proceeds from employee equity incentive plans and exercise of warrants																																					13,504,000
amortization of intangible assets																																						30,630,000	32,795,000	31,182,000	19,564,000	19,399,000	19,555,000	21,750,000	15,751,000	13,513,000	1,862,000	1,862,000	1,862,000	1,862,000	1,862,000	1,862,000	2,044,000	2,057,000	2,057,000	2,057,000	1,822,000	1,732,000	3,374,000	3,488,000	3,845,000	2,121,000	2,280,000	2,288,000
intangible asset impairment																																						0
change in fair value of contingent consideration																																									5,000,000	3,400,000	4,500,000	900,000
repayment of long-term debt																																							-2,505,000	-2,299,000	-1,393,000	-457,186,000	-5,938,000				0
acquisition accounting inventory fair value step-up																																									512,000	1,086,000	1,545,000
liability under government settlement																																												0	0	-7,320,000	95,000	95,000	-1,072,000	-2,904,000	126,000	123,000	121,000	-2,876,000	-2,346,000					0				0
purchases of marketable securities																																												0	-6,815,000	-30,628,000	-67,751,000
proceeds from sale of marketable securities																																												0	66,164,000	15,082,000
proceeds from maturities of marketable securities																																												0	14,150,000	17,838,000									0	0	0	1,004,000	25,000	501,000
purchase of product rights																																												-1,250,000	-8,250,000	-1,250,000	-1,125,000	-1,125,000	-1,125,000	-1,125,000	-1,000,000	-1,000,000	-1,000,000	-1,000,000				-1,000,000	-7,000,000
cash acquired from merger with azur pharma																																														81,751,000
purchases of intangible assets																																											-1,300,000
proceeds from exercise of share options and warrants																																											9,609,000
share-based compensation expense																																												6,612,000	5,258,000	3,281,000
purchase accounting inventory fair value step-up																																												11,442,000
movement in deferred income taxes
other long-term liabilities
decrease in restricted cash
proceeds from employee stock purchases, exercise of stock options and warrants																																												2,422,000			2,951,000	4,057,000
payment of employee withholding taxes upon exercise of share-based awards																																												0	0	-25,299,000
payments of debt extinguishment costs																																															-150,000
net repayments under revolving credit facility
other assets and liabilities																																													-892,000	-299,000
proceeds from exercise of stock options and warrants																																														5,160,000				4,526,000
net repayments under revolving credit facilities																																																-4,000,000	0	-3,350,000
stock-based compensation expense																																															10,946,000	3,195,000	3,415,000	3,148,000	2,250,000	2,177,000	1,960,000	1,832,000	2,448,000	1,313,000	1,114,000	1,082,000	2,316,000	1,688,000	1,875,000	2,227,000	2,287,000	1,793,000
long-term debt, non-cash interest expense																																															0	0	188,000	206,000	231,000
other assets																																															-4,000	69,000				-101,000			-731,000	247,000	-517,000	-4,000	261,000	160,000	-269,000	-232,000	304,000	-266,000
deferred rent																																															0	-12,000	-65,000	-5,000	-4,000	13,000	22,000	22,000	22,000								-85,000	-75,000
decrease (increase) in restricted cash
proceeds from offerings of common stock, net of issuance costs
proceeds from issuance of long-term debt
net (repayments under) proceeds from revolving credit facilities
supplemental disclosure of cash flow information:
cash paid for interest																																																													4,554,000	3,616,000
supplemental disclosure of non-cash investing and financing activities:
liability for purchase of product rights																																																							0	0
warrants to purchase common stock
modification to warrants to purchase common stock issued in conjunction with long-term debt
decrease in restricted cash and investments																																																				510,000	41,000	2,037,000		125,000	-300,000	1,138,000
repayment of senior secured notes																																																			0	0	-116,496,000	-3,000,000					0
proceeds from term loan																																																			-261,000	0
repayment of term loan																																																	-4,166,000	-4,166,000	-4,166,000
gain on sale of product rights																																																											0				-715,000	0
decrease (increase) in restricted cash and investments																																																											85,000	0	0	11,941,000	-1,550,000
transfer of restricted cash to marketable securities
proceeds from sale of product rights																																																											0				1,150,000	0
prepayment penalties and fees
proceeds from employee stock purchases and exercise of stock options and warrants
proceeds from sale of senior secured notes and warrants, net of issuance costs																																																											-28,000	0	-634,000	39,200,000
modification to warrants to purchase common stock issued in conjunction with senior secured notes
loss on extinguishment of debt, non-cash portion																																																				0
proceeds from offering of common stock, net of issuance costs																																																				-302,000
proceeds from private offerings, net of issuance costs
proceeds from employee stock purchases and exercise of stock options																																																				67,000			236,000	25,000			192,000	0
net repayment of revolving credit facilities																																																				0
warrants to purchase common stock issued in conjunction with unregistered sales of equity securities																																																							0
senior secured notes, non-cash interest expense																																																					873,000	1,050,000		701,000
senior secured notes, accrued and unpaid interest
proceeds from exercise of employee stock options																																																						511,000
net repayment of revolving line of credit																																																						-1,559,000
fair value adjustment to acquired finished goods																																																															0	0
revaluation of preferred stock warrant liability																																																															0	0
senior secured notes
increase in restricted cash and investments
net proceeds from line of credit
warrants to purchase common stock issued in conjunction with registered direct public offering																																																											0
warrants to purchase common stock issued in conjunction with senior secured notes																																																											0	0
warrants to purchase common stock issued in conjunction with equity financing facility																																																											0	0
purchases of product rights																																																								-2,000,000
net repayments of line of credit
proceeds from public offerings, net of issuance costs
common stock issued as employee bonuses																																																												0
accrued unpaid interest on senior secured notes
benefit from government settlement																																																									149,000	62,000				-1,818,000
net (repayments of) proceeds from line of credit
accrued unpaid interest for senior secured notes																																																										5,078,000
proceeds from exercise of stock options																																																														2,000
repayment under line of credit																																																										-3,875,000
interest on development financing
gain on extinguishment of development financing
proceeds from sale of property and equipment
proceeds from maturites of long-term restricted cash equivalents
proceeds from issuances of convertible preferred stock, net of issuance costs
proceeds from line of credit																																																													6,100,000	3,179,000	4,307,000	3,308,000
proceeds from development financing
beneficial conversion feature - deemed dividend attributable to preferred stockholders
•
transfer of long-term restricted investments to marketable securities																																																												0	0	-4,410,000
proceeds from sale of common stock in initial public offering, net of issuance costs																																																																-650,000
net (repayments under) proceeds from line of credit
proceeds from sale of common stock in registered direct public offering, net of issuance costs
supplemental disclosure of non-cash financing and investing activities:
conversion of preferred stock warrant liability to stockholders’ equity																																																																0
purchased product rights liability
1.
purchase of developed technology																																																													-10,000,000	-10,000,000
repayments under line of credit																																																													-3,181,000	-3,458,000	-3,445,000	-3,845,000
supplemental disclosure of non-cash financing activities:
fair value of warrants granted under 40.0 million senior notes																																																														2,000,000
purchased in-process research and development
purchases of available-for-sale securities
proceeds from sales of available-for-sale securities
proceeds from maturities of available-for-sale securities
cash paid for shares of orphan medical, inc., net of cash acquired
proceeds from maturites of long term restricted cash equivalents
proceeds from initial public offering
proceeds from sale of senior secured notes, net of issuance costs
warrants to purchase series bb convertible preferred stock issued in conjuction with senior secured notes
beneficial conversion feature—deemed dividend attributable to preferred stockholders
depreciation and amortization																																																																332,000
excess of cash paid over accrued for interest																																																																315,000
gain on extinguishment of development financing obligation
proceeds from issuances of common stock, net of issuance costs																																																																0

We provide you with 20 years of cash flow statements for Jazz Pharmaceuticals plc stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Jazz Pharmaceuticals plc stock. Explore the full financial landscape of Jazz Pharmaceuticals plc stock with our expertly curated income statements.

The information provided in this report about Jazz Pharmaceuticals plc stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.